NVCR News and Press, NovoCure Limited From 11/10/23

Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 20...

2023-11-03 06:45:00 ET Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it. Medical device specialist Novocure (NASDAQ: NVCR) boasts one of the more innovative approac...

2023-10-26 16:35:22 ET Oncology-focused healthcare company Novocure (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its latest set of quarterly results. That decline was notably steep...

2023-10-26 11:17:02 ET NovoCure Limited (NVCR) Q3 2023 Earnings Conference Call October 26, 2023 08:00 ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief ...

2023-10-26 11:00:23 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q3 2023 Earnings Call Oct 26, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q3 2023 Earnings Call Transcript

2023-10-26 07:10:40 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth HC Wainwright cuts NovoC...

CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...

Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most a...

NovoCure Limited (NVCR) is expected to report $-0.51 for Q3 2023

2023-10-25 14:02:09 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth HC Wainwright cuts NovoC...